8-K current report · filed Jul 16, 2026

Arbutus Biopharma Corp (ABUS) 8-K Current Report: July 16, 2026

Item 8.01Item 5.02Item 1.02ABUS overview

Short answer

Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 8.01 (Other Events), Item 5.02 (Departure/Election of Directors or Officers), Item 1.02 (Termination of a Material Definitive Agreement). RSV Agreement terminated after Moderna settlement lacked specific mRESVIA proceeds allocation.

Arbutus Biopharma Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.02 · Termination of a Material Definitive Agreement

  • RSV Agreement terminated after Moderna settlement lacked specific mRESVIA proceeds allocation
  • Genevant to pay Arbutus a $1.0 million termination fee within ten business days
  • All rights and obligations under the RSV Agreement end, removing future allocation claims
  • Termination follows March 2026 settlement resolving global patent litigation with Moderna

Item 5.02 · Departure/Election of Directors or Officers

  • Moderna settlement delivered Arbutus approximately $178 million from a $950 million noncontingent payment, materially strengthening liquidity
  • Additional contingent proceeds up to $1.3 billion remain tied to Moderna’s §1498 appeal and U.S. Government Litigation
  • CEO Lindsay Androski awarded 1.5% of Arbutus’s settlement share, plus 2.0% of future Moderna-related and 2.5% of Pfizer/BioNTech proceeds
  • CFO Tuan Nguyen awarded 0.25% of settlement proceeds, with future Moderna-related bonus subject to board discretion
  • Bonuses create significant management incentives tied to litigation recoveries and continued employment conditions

Item 8.01 · Other Events

  • Patent-enforcement lawsuits filed against Pfizer/BioNTech and affiliates over lipid nanoparticle technology
  • Genevant dividend expected in Q3 2026, but timing and terms remain uncertain
  • Planned shareholder capital return of up to approximately $230 million through potential share repurchases
  • Repurchases require Board approval and depend on receiving the Genevant Parent dividend
  • Litigation outcomes, dividend receipt and capital return remain subject to material execution risks

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Arbutus Biopharma Corp 8-K filings

Get the next ABUS 8-K as it lands

Follow ABUS for push alerts, or ask the research agent what this filing means.